Marnitz Simone, Stuschke Martin, Bohsung Jörg, Moys Anne, Reng Ines, Wurm Reinhard, Budach Volker
Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Charité Campus Mitte, Berlin, Germany.
Strahlenther Onkol. 2002 Nov;178(11):651-8. doi: 10.1007/s00066-002-0939-2.
Local failure is the one of the most frequent cause of tumor related death in locally advanced non-small cell lung cancer (LAD-NSCLC). Dose escalation has the promise of increased loco-regional tumor control but is limited by the tolerances of critical organs.
To evaluate the potential of IMRT in comparison to conventional three-dimensional conformal planning (3DCRT) dose constraints were defined: Maximum dose (D(max)) to spinal cord < 48 Gy, mean lung dose </= 24 Gy, D(max) esophagus > 70 Gy in not more than 5 cm of the total length. For ten patients two plans were compared: (1) 3DCRT with 5 weekly fractions (SD) of 2 Gy to a total dose (TD) of 50 Gy to the planning target volume of second order (PTV2). If the tolerance of the critical organs was not exceeded, patients get a boost plan with a higher TD to the PTV1. (2) IMRT: concomitant boost with 5 weekly SD of 2 Gy (PTV1) and 1.5 Gy to a partial (p)PTV (pPTV=PTV2 profile of a line PTV1) to a TD of 51 Gy to the pPTV and 68 Gy to the PTV1. If possible, patients get a boost plan to the PTV1 with 5 weekly SD of 2 Gy to the highest possibly TD.
Using 3DCRT, 3/10 patients could not be treated with TD > 50 Gy, but 9/10 patients get higher TD by IMRT. TD to the PTV1 could be escalated by 16% on average. The use of non-coplanar fields in IMRT lead to a reduction of the irradiated lung volume. There is a strong correlation between physical and biological mean lung doses.
IMRT gives the possibility of further dose escalation without an increasing mean lung dose especially in patients with large tumors.
局部失败是局部晚期非小细胞肺癌(LAD-NSCLC)中与肿瘤相关死亡的最常见原因之一。剂量递增有望提高局部区域肿瘤控制,但受关键器官耐受性的限制。
为评估调强放疗(IMRT)与传统三维适形放疗(3DCRT)相比的潜力,定义了剂量限制:脊髓最大剂量(D(max))<48 Gy,平均肺剂量≤24 Gy,食管D(max)>70 Gy的长度不超过总长度的5 cm。对10例患者比较了两种计划:(1)3DCRT,每周5次分割(SD),每次2 Gy,至第二级计划靶体积(PTV2)的总剂量(TD)为50 Gy。如果未超过关键器官的耐受性,患者接受对PTV1更高TD的推量计划。(2)IMRT:同步推量,每周5次SD,PTV1为2 Gy,部分(p)PTV(pPTV = PTV2沿PTV1线的轮廓)为1.5 Gy,pPTV的TD为51 Gy,PTV1的TD为68 Gy。如果可能,患者接受每周5次SD、每次2 Gy至最高可能TD的PTV1推量计划。
使用3DCRT时,10例患者中有3例无法接受TD>50 Gy的治疗,但10例患者中有9例通过IMRT获得了更高的TD。PTV1的TD平均可提高16%。IMRT中使用非共面野可减少受照射的肺体积。物理和生物学平均肺剂量之间存在很强的相关性。
IMRT尤其在大肿瘤患者中提供了进一步提高剂量而不增加平均肺剂量的可能性。